Blood glucose lowering and glucagonostatic effects of glucagon-like peptide I in insulin-deprived diabetic dogs

Diabetes

Volumn 46, Issue 5, 1997, Pages 824-828

  Freyse, E J ^a,c   Becher, T ^a   El Hag, O ^a   Knospe, S ^a   Goke B ^b   Fischer, U ^a  

^a UNIVERSITY OF GREIFSWALD   (Germany)

^b PHILIPPS UNIVERSITY MARBURG   (Germany)

^c Institut fur Diabetes 'Gerhardt Katsch'   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCAGON; GLUCAGON LIKE PEPTIDE 1; GLUCOSE; INSULIN;

AMINO ACID METABOLISM; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; DOG; DRUG ACTIVITY; DRUG EFFECT; DRUG SCREENING; FEMALE; GLUCAGON BLOOD LEVEL; GLUCONEOGENESIS; GLUCOSE BLOOD LEVEL; HORMONE ACTION; INSULIN BLOOD LEVEL; INSULIN DEPENDENT DIABETES MELLITUS; MALE; NONHUMAN; PRIORITY JOURNAL;

EID: 0030949882     PISSN: 00121797     EISSN: None     Source Type: Journal    
DOI: 10.2337/diab.46.5.824     Document Type: Article

References (40)

1. Elliot RM, Morgan LM, Tredger JA, Deacon S, Wright J, Marks V: Glucagon-like peptide-1 (7-36) amide and glucose-dependent insulinotropic polypeptide secretion in response to nutrient ingestion in man: acute post-prandial and 24-h secretion patterns. J Endocrinol 138:159-166, 1993
2. Schirra J, Katschinski M, Weidmann C, Schäfer T, Wank U, Arnold R, Göke B: Gastric emptying and release of incretin hormones after glucose ingestion in humans. J Clin Invest 97:92-103, 1996
3. Jia X, Brown JC, Ma P, Pederson RA, McIntosh CHS: Effects of glucose-dependent insulinotropic polypeptide and glucagon-like peptide-I-(7-36) on insulin secretion. Am J Physiol 31:E645-E651, 1995
4. Fieseler P, Bridenbaugh S, Nustede R, Martell J, Orskov C, Holst JJ, Nauck MA: Physiological augmentation of amino acid-induced insulin secretion by GIP and GLP-I but not by CCK-8. Am J Physiol 268:E949-E955, 1995
5. Göke R, Wagner B, Fehmann H-C, Göke B: Glucose-dependency of the insulin stimulatory effect of glucagon-like peptide-1 (7-36) amide on the rat pancreas. Res Exp Med 193:97-103, 1993
6. Dupré J, Behme MT, Hramiak IM, McFarlane P, Williamson MP, McDonald TM: Glucagon-like peptide-I reduces postprandial glycemic excursions in IDDM. Diabetes 44:626-630, 1995
7. Ritzel R, Orskov C, Holst JJ, Nauck MA: Pharmacokinetic, insulinotropic, and glucagonostatic properties of GLP-1 [7-36 amide] after subcutaneous injection in healthy volunteers: dose-response relationships. Diabetologia 38:720-725, 1995
8. Gutniak M, Orskov C, Holst JJ, Ahren B, Efendic S: Antidiabetogenic effect of glucagon-like peptide-1 (7-36) amide in normal subjects and patients with diabetes. N Engl J Med 326:1316-1322, 1992
9. Nauck MA, Kleine N, Orskov C, Holst JJ, Willms B, Creutzfeld W: Normalization of fasting hyperglycaemia by exogenous glucagon-like peptide-1 (7-36 amide) in type 2 (non-insulin-dependent) diabetic patients. Diabetologia 36:741-744, 1993
10. Fehmann HC, Göke R, Göke B: Cell and molecular biology of the incretin releasing polypeptide. Endocrine Rev 16:390-410, 1995
11. D'Alessio DA, Kahn SE, Leusner CR, Ensinck JW: Glucagon-like peptide 1 enhances glucose tolerance by both stimulation of insulin release and by increasing insulin-independent glucose disposal. J Clin Invest 93:2263-2266, 1994
12. D'Alessio DA, Prigeon RL, Ensinck JW: Enterai enhancement of glucose disposition by both insulin-dependent and insulin-independent processes: a physiological role of glucagon-like peptide I. Diabetes 44:1433-1437, 1995
13. Valverde I, Morales M, Clemente F, Lopez-Delgado MI, Delgado E, Perea A, Villanueva-Penacarillo ML: Glucagon-like peptide-1: a potent glycogenic hormone. FEBS Lett 349:313-316, 1994
14. Villanueva-Penacarrillo ML, Alcantara AI, Clemente F, Delgado E, Valverde I: Potent glycogenic effect of GLP-1 (7-36) amide in rat skeletal muscle. Diabetologia 37:1163-1166, 1994
15. Fürnsinn C, Ebner K, Waldhäusl W: Failure of GLP-1 (7-36) amide to affect glycogenesis in rat skeletal muscle. Diabetologia 38:864-867, 1995
16. Ghiglione M, Blazquez E, Uttenthal LO, de Diego JG, Alvarez E, George K, Bloom SR: Glucagon-like peptide-1 does not have a role in hepatic carbohydrate metabolism. Diabetologia 28:920-921, 1985
17. Blackmore PF, Mojsov S, Exton JH, Habener JF: Absence of insulinotropic glucagon-like peptide-I (7-37) receptors on isolated rat liver hepatocytes. FEBS Lett 283:7-10, 1991
18. Freyse EJ, Fischer U, Albrecht G, Salzsieder E: Alterations in alanine metabolism in diabetic dogs during short-term treatment with an artificial B-cell. Diabetologia 28:763-768, 1985
19. Freyse EJ, Rebrin K, Schneider T, Petrzika M, Fischer U: Increased urea synthesis in insulin-dependent diabetic dogs maintained normoglycemic: effect of portal insulin administration and of food protein content. Diabetes 45:667-674, 1996
20. Freyse EJ, Hahn von Dorsche H, Fischer U: Low dose streptozotocin diabetes after partial pancreatectomy in dogs: histological findings in a new type of experimental diabetes. Acta Biol Med Germ 41:203-210, 1982
21. Freyse EJ, Fischer U: Die Bestimmung der spezifischen Aktivitäten von Glucose, Lactat und Alanin aus einer Plasmaprobe bei tracerkinetischen in-vivo-Untersuchungen. Z Med Lab Diagn 28:309-315, 1987
22. Freyse EJ, Fischer U, Albrecht G: Glucose metabolism studied isotopically in diabetic dogs: effect of restoration of peripheral normoinsulinaemia by the artificial B cell. Diabetologia 25:411-417, 1983
23. Wolfe RR: Measurement of urea kinetics in vivo by means of constant tracer infusion of di-15N-urea. Am J Physiol 240:E428-E434, 1981
24. Freyse EJ, Fischer U, Albrecht G, Marx S, Keilacker H: The effect of prehepatic insulin administration on alanine flux rates in diabetic dogs. Diabetologia 30:402-408, 1987
25. Göke R, Cordon JM: Receptors for glucagon-like peptide 1 (7-36) amide on rat insulinoma-derived cells. J Endocrinol 116:357-362, 1988
26. Herrmann C, Göke R, Richter G, Fehmann H-C, Arnold R, Göke B: GLP-1 and GIP plasma levels in response to nutrients. Digestion 56:117-126, 1995
27. Steele R: Influence of glucose loading and of injected insulin on hepatic glucose output. Ann NJ Acad Sci 82:420-430, 1959
28. Hetenyi G: Correction for the metabolic exchange of 14C for 12C atoms in the pathway of gluconeogenesis in vivo. Fed Proc 41:104-109, 1982
29. Orskov C, Rabenhoj L, Wettergren A, Kofod H, Holst JJ: Tissue and plasma concentrations of amidated and glycine-extended glucagon-like peptide I in humans. Diabetes 43:535-539, 1994
30. Kolligs F, Fehmann H-C, Göke R, Göke B: Reduction of the incretin effect in rats by the glucagon-like peptide 1 receptor agonist exendin (9-39) amide. Diabetes 44:16-19, 1995
31. Lefebvre P, Luyckx AS: Factors controlling gastric-glucagon release. J Clin Invest 59:716-722, 1977
32. Fischer U, Freyse EJ: Whole body glucose metabolism in experimental insulin-dependent diabetes after initiation or termination of insulin administration. Exp Clin Endocrinol 94:363-374, 1989
33. Orskov C, Holst JJ, Nielsen OV: Effect of truncated glucagon-like peptide-1 [proglucagon (78-107) amide] on endocrine secretion from pig pancreas, antrum, and nonantral stomach. Endocrinology 123:2009-2013, 1988
34. Suzuki S, Kawai K, Ohashi S, Mukai H, Yamashita K: Comparison of the effects of various C-terminal and N-terminal fragment peptides of glucagon-like peptide-1 on insulin and glucagon release from isolated perfused rat pancreas. Endocrinology 125:3109-3114, 1989
35. Wettergren A, Schjoldager B, Mortensen PE, Myhre J, Christiansen J, Holst JJ: Truncated GLP-1 (proglucagon 78-107-amide) inhibits gastric and pancreatic functions in man. Dig Dis Sci 38:665-673, 1993
36. Wahren J, Felig P, Cerasi E, Luft R: Splanchnic and peripheral glucose and amino acid metabolism in diabetes mellitus. J Clin Invest 51:1870-1878, 1972
37. Matthews DE, Downey RS: Measurement of urea kinetics in humans: a validation of stable isotope tracer methods. Am J Physiol 246:E519-E527, 1984
38. Cherrington AD, Chiasson JL, Liljenquist JE, Jennings AS, Keller U, Lacy WW: The role of insulin and glucagon in the regulation of basal glucose production in the post absorptive dog. J Clin Invest 58:1404-1418, 1976
39. Hendrick GK, Wasserman DH, Frizzell RT, Williams PE, Lacy DB, Jaspan JB, Cherrington AD: The importance of basal glucagon in maintaining hepatic glucose production during a prolonged fast in the conscious dog. Am J Physiol 263:E541-E549, 1992
40. McGuinness OP, Murell S, Moran C, Bracy D, Cherrington AD: The effect of acute glucagon removal on the metabolic response to stress hormone infusion in the conscious dog. Metabolism 43:1310-1317, 1994